Shares Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) climbed Monday after the company reported clinical trial results for one of its experimental hepatitis C drugs. Achillion said all 12 patients who were treated with its drug ACH-3102 and Sovaldi, a blockbuster medication sold by Gilead Sciences Inc., had undetectable levels of the hepatitis C virus after eight weeks. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) belongs to Healthcare sector. Its weekly performance is 6.02%. On last trading day company shares ended up $12.85. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) distance from 50-day simple moving average (SMA50) is 14.55%. Announced Nov 06, A $1.64 billion breakup fee may have placated buyout target Shire ($SHPG) after AbbVie Inc. (NYSE:ABBV) pulled the plug on their $55 billion agreement. AbbVie Inc. (NYSE:ABBV) shares moved up 3.72% in last trading session and ended the day at $63.79. ABBV Gross Margin is 76.80% and its return on assets is 12.90%. AbbVie Inc. (NYSE:ABBV) quarterly performance is 21.62%. Rigrodsky & Long, P.A., including former Special Assistant United States Attorney, Timothy J. MacFall, reminds shareholders of ALTAIR NANOTECH INC (NASDAQ:ALTI) of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company. On 10 November, ALTAIR NANOTECH INC (NASDAQ:ALTI) shares moved up 3.92% and was closed at $1.59. ALTI EPS growth in last 5 year was 32.00%. ALTAIR NANOTECH INC (NASDAQ:ALTI) year to date (YTD) performance is -59.44%. Glimcher Realty Trust (NYSE:GRT) on Nov 03, reported a key measure of profitability in its third quarter. The results matched Wall Street expectations. The Columbus, Ohio-based real estate investment trust said it had funds from operations of $27.6 million, or 19 cents per share, in the period. Glimcher Realty Trust (NYSE:GRT) ended the last trading day at $13.91. Company weekly volatility is calculated as 0.79% and price to cash ratio as 109.56. Glimcher Realty Trust (NYSE:GRT) showed a weekly performance of 0.72%. Announced Nov 06, that Braskem S.A. (NYSE:BAK) 's sales of thermoplastic resins (polyethylene, polypropylene and PVC) grew 5% in the third quarter of 2014 compared to same period last year to reach 939 kton, reflecting third-quarter seasonality and the stronger performance of industries related to durable goods. This performance accompanied the growth in the Brazilian market. Braskem S.A. (NYSE:BAK) shares fell -1.90% in last trading session and ended the day at $14.42. BAK Gross Margin is 13.10% and its return on assets is 2.00%. Braskem S.A. (NYSE:BAK) quarterly performance is 13.45%.
Discover Hidden Gems
Don't miss the next big opportunity. Subscribe for timely alerts on potential market movers.
